Although case numbers in some of our analyses, including subgroup analyses, were low, subgroup analyses and results after adjusting for various parameters, including BRAF/N-RASmut (HR: 0.138, p = 0.000004) and markers of TL such as average LDH (HR 0.306, p = 0.026) and S100P (HR 0.225, p = 0.003), indicate that the relationship between vitamin D status and clinical outcome in melanoma patients treated for metastasized disease with BRAFi/MEKi and/or immunotherapy may at least in part be causal. This evidence concerns the gene BRAF and melanoma.